Tenaya wins FDA RMAT designation for ARVC gene therapy TN-401
Tenaya Therapeutics has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US FDA for TN-401, its investigational AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The designation, awarded on 14 September 2026, was supported by interim data from the ongoing RIDGE-1 Phase 1b/2 clinical trial, which showed clinically meaningful reductions in premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs).
TN-401 now holds three expedited development designations from the FDA: RMAT, Orphan Drug and Fast Track. It also holds PRIME designation from the European Medicines Agency, reflecting a broad regulatory consensus that PKP2-associated ARVC represents a serious unmet medical need. Tenaya said it expects to share further RIDGE-1 data and provide an update on pivotal trial planning discussions with regulators in the fourth quarter of 2026.
What RMAT means in practice
RMAT designation is reserved for regenerative medicine therapies where preliminary clinical evidence indicates potential to address serious conditions. It provides enhanced and more frequent interaction with the FDA, including early guidance on clinical development, manufacturing and regulatory pathways. Crucially, it can confer eligibility for accelerated approval, priority review and rolling review, each of which could materially shorten the timeline to a potential marketing application.
Chief executive Faraz Ali said the designation "underscores the continued recognition by regulators of the seriousness of PKP2-associated ARVC and the potential of TN-401 gene therapy to change the course of disease by addressing its underlying cause."
RIDGE-1 is a multi-centre, open-label, dose-escalation study enrolling up to fifteen adults in the US and UK. Patients must have a confirmed PKP2 mutation, an implantable cardioverter-defibrillator and elevated arrhythmia burden at screening. The interim data presented at the American Society for Gene and Cell Therapy Annual Meeting in May 2026 informed the RMAT application.
Market and competitive context
PKP2 mutations account for roughly 40 per cent of ARVC cases, with an estimated 70,000 people affected in the US alone. Current standard of care, including anti-arrhythmic drugs, ICDs and ablation, manages symptoms without addressing the underlying genetic defect, leaving a substantial therapeutic gap that gene therapy developers are now targeting.
The cardiac gene therapy space is increasingly active. Alongside Tenaya's AAV9 approach, a small number of academic and industry groups are investigating gene editing and RNA-targeting strategies for inherited cardiomyopathies, though few have reached clinical-stage evaluation in ARVC specifically. Tenaya is also running what it describes as the largest natural history study in adult PKP2-associated ARVC patients, a dataset that could strengthen both regulatory submissions and label negotiations if TN-401 advances to a pivotal trial.
The company's pipeline extends beyond ARVC: TN-201 targets MYBPC3-associated hypertrophic cardiomyopathy and TN-301 is a small-molecule HDAC6 inhibitor being evaluated in heart failure and Duchenne muscular dystrophy, offering investors some diversification against single-asset risk. Near-term attention will focus on the Q4 2026 RIDGE-1 data readout and any clarity on pivotal trial design, which will be the principal determinants of TN-401's development trajectory.